Studies suggest that undiagnosed endometriosis results in poor reproductive outcomes in the
setting of In Vitro Fertilization and Embryo Transfer (IVF-ET). Biomarkers that predict
endometriosis including B-cell lymphoma (BCL6) and Sirtuin 1 (SIRT1) are associated with
reduced pregnancy rates following IVF-ET. Treatment with gonadotropin releasing hormone
(GnRHr) receptor agonists (leuprolide acetate depot) has been shown to improve pregnancy
rates following embryo transfer (ET). In this randomized controlled trial, a new generation
GnRHr antagonist, elagolix, will be compared to oral contraceptives (OCPs) for suppression of
suspected endometriosis prior to ET. Both groups will receive two months of treatment prior
to frozen embryo transfer of a single euploid embryo. Outcomes will include pregnancy rate,
miscarriage rate and ongoing and live birth rate following treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborators:
Stanford University University of North Carolina, Chapel Hill